Access to Precision Oncology with Decentralized Liquid Biopsy Solutions

Thursday, February 29, 3:00pm - 3:30pm (EST)

Time shown in-04:00 America, New York

Liquid biopsy is emerging as a revolutionary technology, holding promise for swift and precise diagnostics. Despite the potential to positively impact precision oncology and the increasing popularity of NGS-based assays, liquid biopsy faces challenges, including workflow standardization across the globe, regulatory issues, guideline inclusion, and reimbursement hurdles.

Join us in this talk to hear about the SOPHiA GENETICS' journey in expanding access to Liquid Biopsy at a global scale.

Understand the vital role of decentralizing liquid biopsy testing for early detection, patient identification, and treatment monitoring
Learn about SOPHiA DDM™ Liquid Biopsy (LBx) Solutions and the power of our decentralized and technology-agnostic SOPHiA DDM™ Platform
Hear about SOPHiA GENETICS’ collaboration with MSK and AstraZeneca, aiming to expand global access to advanced cancer testing and accessibility through MSK- ACCESS® powered by the SOPHiA DDM™ Platform

Speakers:

T. Scott Reid, PhD – VP, Global Head of Diagnostics, SOPHiA GENETICS

Add to Calendar 2024/02/29 12:00:00 2024/02/29 12:30:00 America/Los_Angeles Access to Precision Oncology with Decentralized Liquid Biopsy Solutions Liquid biopsy is emerging as a revolutionary technology, holding promise for swift and precise diagnostics. Despite the potential to positively impact precision oncology and the increasing popularity of NGS-based assays, liquid biopsy faces challenges, including workflow standardization across the globe, regulatory issues, guideline inclusion, and reimbursement hurdles.

Join us in this talk to hear about the SOPHiA GENETICS' journey in expanding access to Liquid Biopsy at a global scale.

Understand the vital role of decentralizing liquid biopsy testing for early detection, patient identification, and treatment monitoring
Learn about SOPHiA DDM™ Liquid Biopsy (LBx) Solutions and the power of our decentralized and technology-agnostic SOPHiA DDM™ Platform
Hear about SOPHiA GENETICS’ collaboration with MSK and AstraZeneca, aiming to expand global access to advanced cancer testing and accessibility through MSK- ACCESS® powered by the SOPHiA DDM™ Platform

Speakers:

T. Scott Reid, PhD – VP, Global Head of Diagnostics, SOPHiA GENETICS

8th Annual Liquid Biopsy for Precision Oncology Summit, Track B: Clinical Development & Commercialization false MM/DD/YYYY 15 OPAQUE aqNiQkClzzVvhRIwimiY251270

8th Annual Liquid Biopsy for Precision Oncology Summit, Track B: Clinical Development & Commercialization

Field Marketing, fieldmarketing@sophiagenetics.com

Link: